Independent Editorial Rankings
We independently rank GLP-1 telehealth providers, weight loss programs, and the pharmacies behind them — so you can save money without falling for sketchy ads.
Reader-supported. When you sign up with a provider through our links we may earn a commission at no extra cost to you. How we make money.
Why readers use us
Brand-name Wegovy retails for around $1,349/month without insurance. The median compounded semaglutide provider in our dataset charges $169/month— same active ingredient, same weekly injection, a fraction of the cost.
Cheapest first-month rate currently in our dataset: $49/mo. Introductory pricing varies by provider and typically increases after the first month — always verify on the provider's site before signing up.
Quick Match
Three questions. We'll instantly show you the highest-rated provider that matches your budget, state, and preference — based on real pricing data.
Featured Partners
Best for mainstream telehealth GLP-1 access
“Both semaglutide and tirzepatide available”
Best for compounded GLP-1 access with named prescribers and 4-pharmacy network
Best for Needle-free, microdosed compounded GLP-1 with lab-monitored care
Every provider in our dataset has a first-party editorial review with a six-dimension score, verified pricing, state coverage, and primary-source citations. Read what we found before signing up.
Use our savings calculator to see what you could pay — then compare providers side by side to find the best deal.
Interactive pharmacokinetic simulator showing how semaglutide, tirzepatide, and Foundayo (orforglipron) build up across the standard FDA titration schedule.
6-drug interactive timeline showing when nausea peaks, when it resolves, and what every other GLP-1 side effect looks like by week. Every cell anchored to a primary source.
Coverage Map
Click any state to see the providers that ship and prescribe there. Darker squares mean more provider options available.
Coverage data compiled from 585 GLP-1 telehealth providers tracked by Weight Loss Rankings.
Editorial flagship
Primary-source deep-dives on GLP-1 weight-loss medications, every claim cited from FDA prescribing information and PubMed.
GLP-3 is not a real hormone, receptor, or approved drug. The term is a nickname for retatrutide, an investigational triple agonist that activates GLP-1, GIP, and glucagon receptors. We explain what is actually real (GLP-1 and GLP-2), why the “next generation” framing is wrong, and what is being sold under the GLP-3 label.
Read the analysis→Cagrilintide is a once-weekly amylin analog from Novo Nordisk and the other half of CagriSema. Neither has FDA approval. We cover what amylin analogs actually are, the pooled trial evidence across 5,425 participants, and why there is no cagrilintide dosage chart to follow.
Read the analysis→Mazdutide is a glucagon/GLP-1 dual agonist approved in China for chronic weight management but unavailable in the US. We cover what the approval actually authorizes, how it differs from tirzepatide and retatrutide, and why an approval abroad does not make a US-sold vial legitimate.
Read the analysis→A clinician-informed 7-day plan, protein & fiber targets, food lists, and a grocery list — sent straight to your inbox.